If there are residual bubbles in the pre filled syringe during the filling process, it may cause the following serious consequences, which need to be highly valued:

1. Inaccurate dosage

·Key impactsBubbles occupy the volume of the medication, causing the actual dosage to be lower than the standard, which affects the therapeutic effect (especially for narrow treatment window drugs such as vaccines, insulin, or chemotherapy drugs).

·Risk scenarioIn pediatrics or high-precision medication, small dose deviations may lead to ineffectiveness or toxicity.

2. Drug stability and safety

·Oxidation/degradationSome drugs (such as biologics and protein drugs) may accelerate oxidation or aggregation, reduce potency, or produce harmful substances when exposed to bubbles.

·Particulate pollutionBubble rupture may cause liquid level fluctuations, increasing the risk of glass debris or rubber stopper particles falling off.

3. Clinical use risks

·Risk of embolismDuring intravenous injection, a large amount of air bubbles (usually>0.5mL) may cause gas embolism and block blood vessels; Subcutaneous/intramuscular injection may cause local tissue damage or pain.

·Operational obstaclesMedical staff need to exhaust additional air, increase operational steps and pollution probability, and delay treatment in emergency situations.

4. Product quality and compliance issues

·appearance defectBubbles are considered visible foreign objects and may result in batch scrapping or recall, violating GMP and pharmacopoeia standards.

·regulatory penaltyNot meeting the mandatory requirements of FDA or EMA for injections to have "no visible bubbles" and facing legal risks.

5. Additional risks associated with special dosage forms

·Viscous drug(such as monoclonal antibodies): Bubbles are difficult to expel and may interfere with the dose push mechanism of automatic injectors (such as pre filled pens).

·Freeze dried productsResidual bubbles during reconstitution may affect dissolution efficiency.

Solutions and preventive measures

·process optimizationAdopting vacuum filling, pressure filling or ultrasonic degassing technology.

·Equipment CalibrationEnsure that the insertion depth, speed, and angle of the filling needle reduce turbulence.

·Strengthen quality inspectionOnline visual inspection.

·personnel trainingStandardize the operating procedures to avoid introducing bubbles during manual filling.

Shanghai Yaoshun's pre filled syringe filling machine has passedMultiple technological optimizationsandProcess innovationIt can effectively solve the problem of residual bubbles during the filling process. Here are its key solutions and advantages:

1. Core solution technology for bubble problem

(1) Vacuum filling system

·Technical PrincipleBefore filling, evacuate the syringe cavity to reduce air residue, and then inject the medication.

·effectReduce the probability of bubble generation (especially for high viscosity drugs such as biologics).

(2) Pressure filling control

·Dynamic pressure regulationWhen inserting the filling needle into the medication, closed-loop pressure control is used to avoid turbulence and gas entrapment.

·applicabilitySuitable for sensitive drugs that are prone to oxidation, such as vaccines and monoclonal antibodies.

2. Key optimization of filling process

·Accurate positioning of filling needles：

·Using servo motors to control the depth and angle of needle insertion, ensuring smooth injection of medication and avoiding splashing and bubble mixing.

·Low speed filling mode：

·Reduce the filling speed to minimize shear force for easily foaming drugs (such as formulations containing surfactants).

3Ability to adapt to complex dosage forms

·High viscosity liquid medicine: Equipped withCeramic pump orPiston pump ensures uniform filling without bubbles.

·Freeze dried productsSupport inert gas (such as nitrogen) protection filling for pre filled syringes to avoid reconstitution issues.

4Industry validation and compliance

·Compliant with GMP requirementsEquipment design meets GM requirementsPData integrity standards.

·practical case: Applied domesticallyoutsidePre encapsulation production of multiple biopharmaceutical companies.